Searched for
HIGH POTENCY API
Holding stocks is harder than finding them: 10 mid- and small-caps stocks that may be worth holding on toHolding a stock is not an act of blind faith. It is not refusing to change one’s mind. It is not averaging down because the stock has falle...- As headwinds slow & managements become realistic, time for a relook: 5 mid-cap pharma stocks with upside potential of up to 44%Every sector goes through a phase when managements become over-optimistic, taking decisions that should have been avoided. But then, with t...
- Listen beyond the noise from Trump, think beyond Nifty’s volatility: 8 mid and 1 small cap pharma stock with upside potential of up to 46%With the Nifty moving up for just two days, have we forgotten what happened to stock prices in the past six months? This is where we all ma...
- Looking at mid-caps? Keep your portfolio healthy: 5 mid-cap pharma stocks with an upside potential of up to 38%Even as the bears are running wild on the street causing across-the-board damage, there are sectors that have kept them at bay. And that’s ...
- Necessary pill for portfolio during volatility and Trump tariff wars: 8 pharma stocks with an upside potential of up to 48%Let’s accept the fact that we are likely to be dealing with volatility for the next four years. Both in the real world and in the global an...
- Decline in rupee: Besides IT, there are other winners as well; 9 pharma stocks with an upside potential of up to 40%The relationship between a decline in the rupee and better margins for IT companies is well known. What is not discussed much is that pharm...
- Own midcaps? Do a check & balance exercise to avoid decision of haste: 7 midcaps from different sectors with an upside potential of upto 49%Every now and then the market goes through phases, where it prefers a certain set of stocks, not based on sector but based on the overall m...
- Comeback and re-rating supported by numbers? 5 pharma stocks with upside potential of up to 21%Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant ch...
- Corrections are opportunities for long term investors: 5 midcaps with right mix and upside potential of up to 46%For the next couple of weeks, what will dominate the narrative on the street would be the action and expectation from the US Fed and Iran’s...
- For high risk averse: 5 midcap stocks from different sectors with potential upside of up to 20%In the last two months of the market, while the midcaps have done well, though the pace at which the outperformance was taking place has sl...
- For investors with moderate risk appetite? 5 midcap stocks with right RoE and upside potential of up to 44%In a market where bulls are ruling every corner of the street, and stocks are either fairly valued or overvalued. The big question is how d...
- Tailwinds at the right time: 7 pharma stocks with an upside potential up to 37 %It is not very common to see tailwinds emerging for an industry at a time when it is ideal to own stocks from that space. But in the case o...
- A Healthy Dose! 4 midcap pharma stocks with upside potential of up to 36%After a long period of under performance, pharma stocks have seen interest coming back from institutional investors. This is because some t...
- Finally out of the woods? 4 midcap pharma stocks with an upside potential up to 34 %Pharma stocks had been underperforming for a very long time. Some time USFDA issues, at other instances of pricing pressure in US markets h...
- The race is on: Last-mile delivery companies are playing their part in Covid-19 vaccinationAs India battles to vaccinate its population, private players will prove to be critical in meeting the inoculation targets.
- Piramal Pharma Solutions invests around USD 32 mn to expand Michigan facilityThe expansion is planned to be ready for customers beginning summer 2022. It is expected that the expansion will add around twenty new hire...
- Piramal Enterprises touches record high on Ash Stevens buyThe stock was the top gainer on Nifty Pharma index on Wednesday and was among the top gainers in the Nifty Midcap 100 pack.
- Piramal Enterprises to acquire Ash Stevens Inc for more than Rs 350 crore"Ash Stevens will add high potency capabilities to the services we offer our customers," Vivek Sharma, Pharma Solutions business CEO, Piram...
- Dishman to chase high-potency therapiesDishman Pharmaceuticals Ltd, will now focus on the high-potency therapies like steroids, hormones, isotopes and cytotoxics.
- Dishman acquires Solvay's fine chemicalsDishman will acquire the fine chemicals, vitamin D and vitamin D analogues business of Solvay Pharma.
Load More
